Long-term in vitro recording of cardiac action potentials on microelectrode arrays for chronic cardiotoxicity assessment

Figures

• 

  Fig. 1. Long-term intracellular AP recordings from hiPSC-CMs. a Photograph of a 6-well MEA (60-6wellMEA200/30iR-Ti-rcr). b hiPSC-CMs at 9DIVs in a single MEA well. c Representative scheme of laser-based optoporation on 6-well MEA devices. d Time course of APs recording. e Action potential mean waveforms of cardiac syncytium in a well of 6-well MEA at different DIVs. f Immunofluorescence images at 20× magnification of hiPSC-CMs on 6-well MEA after 6 repeated opotoporation procedures and at 60× magnification of the area highlighted with white box. Scale bar: 30 µm

• 

  Fig. 2. Long-term intracellular AP recordings from hiPSC-CMs. a, b Action potential duration at different amplitudes (APD30, 50, 90) and beating rate for two different wells of a 6-well MEA. c Comparison of the APD at 50% repolarization (APD50) of each well over time. d Standard error of the mean (SEM) of APD50 among wells. Data are represented as mean ± SEM

• 

  Fig. 3. Long-term intracellular AP recordings from single cardiac cells. a Photograph of a well of 6-well MEA (60-6wellMEA200/30iR-Ti-rcr). b Action potential waveform of single cells in a well of a 6-well MEA at different DIVs. c, d Action potential duration at different amplitudes (APD30, 50, 90) from two single electrodes in two different wells

• 

  Fig. 4. Long-term effect of pentamidine on hiPSC-CMs. a, b Action potential mean waveforms at different days after 0.5 and 1.5 µM pentamidine administration, respectively. c, d Action potential duration at different amplitudes (APD30, 50, 90) after 0.5 and 1.5 µM pentamidine administration, respectively. e, f Beating rate after 0.5 and 1.5 µM pentamidine administration, respectively. Data are represented as mean ± SEM of 3 wells

• 

  Fig. 5. Long-term effect of doxorubicin on hiPSC-CMs. a, b Action potential mean waveforms at different days after 5 and 10 nM doxorubicin administration, respectively. c, d Action potential duration at different amplitudes (APD30, 50, 90) after 5 and 10 nM doxorubicin administration, respectively. e, f Beating rate after 5 and 10 nM doxorubicin administration in different wells. Data are represented as mean ± SEM of 3 wells